183 related articles for article (PubMed ID: 36111466)
1. [Treatment and progress of cutaneous neurofibroma].
Zhu B; Wei C; Wang W; Gu B; Li Q; Wang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Sep; 36(9):1064-1071. PubMed ID: 36111466
[TBL] [Abstract][Full Text] [Related]
2. Management of cutaneous neurofibroma: current therapy and future directions.
Chamseddin BH; Le LQ
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i107-i116. PubMed ID: 32642736
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous neurofibromas: Current clinical and pathologic issues.
Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
[TBL] [Abstract][Full Text] [Related]
4. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
5. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
6. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.
Guiraud M; Bouroubi A; Beauchamp R; Bocquet A; Grégoire JM; Rauly-Lestienne I; Blanco I; Wolkenstein P; Schmitt AM
Orphanet J Rare Dis; 2019 Dec; 14(1):286. PubMed ID: 31801570
[TBL] [Abstract][Full Text] [Related]
8. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
[TBL] [Abstract][Full Text] [Related]
9. Activation of PLCγ/AKT/IκBα/p65 signaling increases inflammation in mast cells to promote growth of cutaneous neurofibroma.
Xu J; Zhang H; Li C; Du H; Shu M; Jia J
Life Sci; 2019 Dec; 239():117079. PubMed ID: 31756343
[TBL] [Abstract][Full Text] [Related]
10. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
[TBL] [Abstract][Full Text] [Related]
11. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
[TBL] [Abstract][Full Text] [Related]
12. Creating a comprehensive research strategy for cutaneous neurofibromas.
Blakeley JO; Wolkenstein P; Widemann BC; Lee J; Le LQ; Jackson R; Stathis M; Verma SK
Neurology; 2018 Jul; 91(2 Suppl 1):S1-S4. PubMed ID: 29987129
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial design for cutaneous neurofibromas.
Cannon A; Jarnagin K; Korf B; Widemann BC; Casey D; Ko HS; Blakeley JO; Verma SK; Pichard DC
Neurology; 2018 Jul; 91(2 Suppl 1):S31-S37. PubMed ID: 29987133
[TBL] [Abstract][Full Text] [Related]
14. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous neurofibroma cells with active YAP promotes proliferation of macrophages resulting in increased accumulation of macrophages by modulating CCL5 and TGF‑β1.
Jia J; Zhang H; He L; Zhang H; Shu M
Oncol Rep; 2020 Apr; 43(4):1319-1330. PubMed ID: 32323813
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
Peltonen S; Jannic A; Wolkenstein P
Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
[TBL] [Abstract][Full Text] [Related]
18. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Cutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.
Wozniak B; Bove T; Zawada T; Calik J
Case Rep Dermatol; 2023; 15(1):194-201. PubMed ID: 37899948
[TBL] [Abstract][Full Text] [Related]
20. Activated androgen receptor accelerates angiogenesis in cutaneous neurofibroma by regulating VEGFA transcription.
Jia J; Zhang H; Zhang H; Du H; Liu W; Shu M
Int J Oncol; 2019 Jul; 55(1):157-166. PubMed ID: 31059067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
